Skip to main content
. 2024 Apr 24;9(5):102924. doi: 10.1016/j.esmoop.2024.102924

Table 2.

Progression-free survival summary

Patients with BMs (n = 82)
Patient without BMs (n = 442)
T-DXd (n = 43) T-DM1 (n = 39) T-DXd (n = 218) T-DM1 (n = 224)
Median PFS (95% CI), months 15.0 (12.5-22.2) 3.0 (2.8-5.8) NR (22.4-NE) 7.1 (5.6-9.7)
HR 0.25 (95% CI 0.13-0.45) HR 0.30 (95% CI 0.22-0.40)
12-month PFS rate (95% CI), % 72.0 (55.0-83.5) 20.9 (8.7-36.6) 76.5 (70.0-81.8) 36.4 (29.4-43.4)
Median PFS, patients without prior BM therapy (95% CI), months 16.8 (12.4-NE)
(n = 20)
5.6 (2.8-5.8)
(n = 19)
HR 0.16 (95% CI 0.06-0.44)
Median PFS, patients with prior BM therapy (95% CI), months 14.1 (8.5-18.5)
(n = 23)
2.8 (2.6-NE)
(n = 20)
HR 0.35 (95% CI 0.15-0.79)

BMs, brain metastases; CI, confidence interval; HR, hazard ratio; NE, not estimable; NR, not reached; PFS, progression-free survival; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan.